Meeting
2013 ASCO Annual Meeting
BIM deletion polymorphism to predict systemic treatment outcome in advanced non-small cell lung cancer.
Authors
Jih-hsiang Lee
Department of Oncology, National Taiwan University Hospital, Taipei, Taiwan
Jih-hsiang Lee , Yu-lin Lin , Hsuan-Yu Chen , Yeun-Chung Chang , Chong-Jen Yu , Jin-Yuan Shih , Kuan-Yu Chen , Pan-Chyr Yang , Chih-Hsin Yang
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Lung Cancer - Non-small Cell Metastatic
Track
Lung Cancer
Sub Track
Metastatic Non–Small Cell Lung Cancer
Citation
J Clin Oncol 31, 2013 (suppl; abstr 8055)
DOI
10.1200/jco.2013.31.15_suppl.8055
Abstract #
8055
Poster Bd #
34C
Abstract Disclosures
Similar Posters
Poster
2011 ASCO Annual Meeting
Final overall survival results of NEJ002, a phase 3 trial comparing gefitinib to carboplatin (CBDCA) plus paclitaxel (TXL) as the first-line treatment for advanced non-small cell lung cancer (NSCLC) with EGFR mutations.
First Author: A. Inoue
Poster
2018 ASCO Annual Meeting
Quality of life analysis of Pemetrexed versus Erlotinib maintenance in EGFR mutation negative advanced non small cell lung cancer.
First Author: Vivek Agarwala
Poster
2017 ASCO Annual Meeting
Gefitinib as third-line re-challenge treatment in advanced NSCLC patients with EGFR activating mutation who benefited from first-line gefitinib treatment followed by second-line chemotherapy.
First Author: Yong Song
Poster
2014 ASCO Annual Meeting
Final overall survival results of WJTOG 3405, a randomized phase 3 trial comparing gefitinib (G) with cisplatin plus docetaxel (CD) as the first-line treatment for patients with non-small cell lung cancer (NSCLC) harboring mutations of the epidermal growth factor receptor (EGFR).
First Author: Hiroshige Yoshioka